Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Escape room by Parkinson's NSW

Global update

No Escape Room: a Parkinson’s campaign like no other

The escape room simulates common Parkinson’s symptoms

READ MORE
Prof Volkmann Parkinson Treatment

sponsored article

Advances

Hitting the sweet spot: how the new directional DBS system improves symptom control in Parkinson’s disease

New tech can find the brain’s ‘sweet spot’ for improved effectiveness

READ MORE

Women and Parkinson's

The women blazing the trail in Parkinson’s tech and innovation

Have you heard about these Parkinson’s technology inventions?

READ MORE